Wall Street analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to report $140.76 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Medidata Solutions’ earnings, with estimates ranging from $140.20 million to $141.34 million. Medidata Solutions posted sales of $124.47 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.1%. The firm is scheduled to report its next quarterly earnings results on Thursday, February 8th.
On average, analysts expect that Medidata Solutions will report full-year sales of $140.76 million for the current fiscal year, with estimates ranging from $544.50 million to $546.00 million. For the next year, analysts expect that the company will report sales of $641.57 million per share, with estimates ranging from $635.19 million to $650.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The company had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. Medidata Solutions’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the business earned $0.28 EPS.
A number of brokerages have weighed in on MDSO. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Royal Bank of Canada began coverage on shares of Medidata Solutions in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $82.00 price target on the stock. Dougherty & Co began coverage on shares of Medidata Solutions in a report on Thursday, November 2nd. They issued a “neutral” rating on the stock. KeyCorp reiterated a “buy” rating and issued a $86.00 price target on shares of Medidata Solutions in a report on Sunday, September 17th. Finally, Deutsche Bank began coverage on shares of Medidata Solutions in a report on Friday, December 8th. They issued a “buy” rating and a $78.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $84.54.
Medidata Solutions (NASDAQ:MDSO) opened at $64.87 on Friday. The firm has a market cap of $3,787.69, a price-to-earnings ratio of 78.06, a price-to-earnings-growth ratio of 3.36 and a beta of 1.69. Medidata Solutions has a 1-year low of $47.77 and a 1-year high of $85.92. The company has a quick ratio of 3.37, a current ratio of 1.29 and a debt-to-equity ratio of 0.61.
In related news, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $65.40, for a total transaction of $130,800.00. Following the transaction, the chief financial officer now owns 91,775 shares in the company, valued at approximately $6,002,085. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Taylor sold 5,000 shares of Medidata Solutions stock in a transaction on Monday, November 6th. The shares were sold at an average price of $71.39, for a total transaction of $356,950.00. Following the transaction, the director now owns 49,372 shares in the company, valued at approximately $3,524,667.08. The disclosure for this sale can be found here. Insiders have sold a total of 239,010 shares of company stock worth $16,437,036 in the last 90 days. Company insiders own 5.80% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. 1st Global Advisors Inc. lifted its holdings in shares of Medidata Solutions by 0.5% during the 2nd quarter. 1st Global Advisors Inc. now owns 8,243 shares of the company’s stock valued at $645,000 after acquiring an additional 37 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Medidata Solutions by 0.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 33,828 shares of the company’s stock valued at $2,645,000 after acquiring an additional 109 shares in the last quarter. Pinebridge Investments L.P. lifted its holdings in shares of Medidata Solutions by 2.1% during the 2nd quarter. Pinebridge Investments L.P. now owns 7,305 shares of the company’s stock valued at $572,000 after acquiring an additional 153 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Medidata Solutions by 10.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after acquiring an additional 208 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Medidata Solutions by 0.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 82,279 shares of the company’s stock valued at $6,435,000 after acquiring an additional 526 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://ledgergazette.com/2018/01/13/140-76-million-in-sales-expected-for-medidata-solutions-inc-mdso-this-quarter.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.